Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology Business Group. In this role, Mr. Hawthorne will be responsible for leading the U.S. Neurology Sales and Marketing teams in bringing Eisai's neurology portfolio of products to patients.
Mr. Hawthorne brings to Eisai significant expertise in transformational leadership, building and leading high performance teams, new product launches, P&L management, and lifecycle management.
"With his proven record for driving organizational and brand growth, we are excited to have Paul on our team," said Ivan Cheung, Chairman and CEO of Eisai Inc. and President of the Neurology Business Group. "We look forward to his contributions to our commercial organization to maximize our neurology brands, and help in ensuring that the appropriate patients have access to our products."
Mr. Hawthorne joins Eisai from Sanofi, where he spent the last 24 years in positions of increasing responsibility across all commercial functions and multiple therapeutic areas. Most recently, he held the position of Vice President (VP) of Sales, in which he was responsible for leading retail, hospital and long-term care sales forces through three product launches in the last 18 months. Prior roles include serving as VP & Head of Go To Market Center of Excellence and as VP & Head of the Oncology Business Unit.
Mr. Hawthorne holds a Master of Business Administration in Marketing from LaSalle University. He earned his Bachelor of Arts degree in Communications from the University of Pittsburgh.